Does Blue Cross Blue Shield of Michigan Cover Prolia?

What Is Prolia and Why Does Coverage Matter?

Prolia is the brand name for denosumab, a fully human monoclonal antibody that inhibits RANK ligand (RANKL), blocking osteoclast formation and reducing bone resorption. The FDA approved it on June 1, 2010, for postmenopausal women with osteoporosis at high fracture risk, and the label has since expanded to include men with osteoporosis, bone loss from androgen deprivation therapy, and bone loss from aromatase inhibitor therapy in women with breast cancer. [1]

Cost is the central issue for most patients. At a 2024 wholesale acquisition cost of roughly $1,390 per injection and a dosing schedule of every 6 months, the annual drug cost before insurance approaches $2,780. That figure alone explains why understanding your specific BCBSM plan is not optional.

How Denosumab Reduces Fracture Risk

The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo over 36 months (P<0.001 for all endpoints). [2] These are among the largest fracture-reduction estimates in the osteoporosis literature, which is part of why prescribers and payers take this drug seriously.

Who Receives an FDA-Approved Indication

The FDA-approved indications relevant to BCBSM coverage decisions include:

• Postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture, or multiple risk factors for fracture)
• Men with osteoporosis at high fracture risk
• Men receiving androgen deprivation therapy for nonmetastatic prostate cancer
• Women receiving adjuvant aromatase inhibitor therapy for breast cancer [1]

Coverage outside these indications, such as premenopausal bone loss from glucocorticoid use, may require additional documentation.

How BCBSM Formularies Classify Prolia

BCBSM operates several distinct plan types, and the formulary tier for Prolia differs across them.

Commercial PPO and HMO Plans

On standard BCBSM commercial plans, Prolia sits on the specialty tier, typically Tier 4 or Tier 5. Specialty tier cost-sharing commonly means a coinsurance percentage of 20-30% rather than a flat copay. On a plan with 20% coinsurance and no specialty drug deductible already met, one injection could cost a member $278 out of pocket at WAC. If the specialty deductible has not been satisfied, costs are higher still.

BCBSM's publicly available Summary of Benefits documents, posted annually on bcbsm.com, specify specialty cost-sharing by plan. Members should download the Evidence of Coverage (EOC) document for their specific plan year and look for the "specialty medications" or "self-administered drugs" section.

Medicare Advantage and Part D Plans

BCBSM administers several Medicare Advantage plans in Michigan, including BCBSM Medicare Plus Blue PPO and BCN Advantage HMO. Under Medicare, Prolia is typically covered under the medical benefit (Part B) rather than the pharmacy benefit (Part D), because it is administered by a healthcare provider in an office setting. [3]

Under Part B, Medicare pays 80% of the allowed amount after the Part B deductible ($240 in 2024). The member is responsible for the remaining 20% coinsurance, which on a $1,390-WAC drug translates to roughly $278 per dose. Medicare Advantage plans may cap this exposure, but the cap varies by plan.

State Employee Plans (BCBSM MESSA and Michigan State)

State of Michigan employees and teachers often carry BCBSM-administered plans through MESSA or the Michigan Civil Service Commission. These plans generally follow BCBSM commercial formulary structures but may have distinct prior authorization criteria negotiated at the group level. Members should contact MESSA directly or review the specific group EOC.

Prior Authorization Requirements for Prolia Under BCBSM

Prior authorization (PA) is required for Prolia on virtually every BCBSM plan. Submitting an incomplete PA is the single most common reason for denial.

Standard Clinical Criteria BCBSM Applies

BCBSM's medical policy for denosumab (referenced under policy number MED-0016 or equivalent specialty pharmacy policy) generally requires documentation of all of the following:

1. A diagnosis of osteoporosis confirmed by dual-energy X-ray absorptiometry (DXA) with a T-score of <-2.5 at the lumbar spine, total hip, or femoral neck, OR a documented low-trauma (fragility) fracture.
2. The patient meets an FDA-approved indication.
3. Either prior trial of at least one oral bisphosphonate (alendronate, risedronate, or ibandronate) for a minimum of 3-6 months, OR a documented medical contraindication or intolerance to bisphosphonates (such as esophageal disease, renal impairment with GFR <35 mL/min, or severe GI intolerance). [4]
4. A prescribing clinician who is a physician, PA, or NP with relevant specialty training or clinical experience in metabolic bone disease.

The AACE/ACE 2020 Clinical Practice Guidelines on Postmenopausal Osteoporosis state that "denosumab is appropriate as a first-line agent in patients who cannot tolerate or absorb oral bisphosphonates, or who have renal insufficiency," which directly supports PA approval in these subgroups. [5]

What Your Prescriber Should Submit

A successful PA packet for Prolia under BCBSM typically includes:

• The completed BCBSM PA form (downloadable from bcbsm.com/providers)
• DXA report with T-scores and Z-scores
• Fracture history (radiology reports if applicable)
• Documentation of bisphosphonate trial or contraindication (office notes, pharmacy records, or a formal letter of medical necessity)
• Serum creatinine or eGFR if renal contraindication is claimed
• Most recent FRAX score if available

Missing even one of these items can delay approval by 2-4 weeks or trigger an outright denial.

Renewal PA Requirements

BCBSM generally requires re-authorization every 12 months. At renewal, the prescriber must document ongoing clinical benefit. Acceptable evidence includes stable or improved DXA T-score, absence of new fragility fractures on the current regimen, or clinical judgment that the patient remains at high fracture risk per the FRAX algorithm. [6] Bone turnover markers such as serum CTX (C-telopeptide) may also be submitted to demonstrate biochemical response.

What Happens After a Denial

A first-level denial from BCBSM is not a final answer. Michigan law and federal regulations under the Affordable Care Act give members the right to both internal and external appeals.

Internal Appeal

File the internal appeal within 180 days of the denial notice. The appeal should include:

• A letter of medical necessity from the prescribing physician citing the AACE/ACE 2020 guidelines [5] and the FREEDOM trial fracture data [2]
• Any missing documentation from the original PA submission
• Peer-reviewed literature supporting use in the patient's specific clinical subgroup

Internal appeals are reviewed by a different BCBSM clinical reviewer than the one who issued the denial. Resolution is required within 30 days for non-urgent requests and 72 hours for urgent clinical situations under Michigan law.

External Independent Review

If the internal appeal is denied, members can request an external independent review through the Michigan Department of Insurance and Financial Services (DIFS). The external reviewer is not employed by BCBSM and makes a binding determination. Studies of external appeals for specialty medications suggest that patients win reversal in approximately 40-60% of cases when the appeal includes complete clinical documentation and a physician letter citing current guidelines. [7]

Step Therapy Exceptions

Some BCBSM plans use step therapy protocols requiring bisphosphonate failure before approving Prolia. Michigan's Step Therapy Reform Act (Public Act 352 of 2018) requires health insurers to grant a step therapy exception when the required first-step drug is contraindicated, has been tried and failed, or would cause clinically significant harm. Your prescriber can request a step therapy exception using this state law as use. [8]

Out-of-Pocket Cost Reduction Strategies

Even with coverage, specialty tier cost-sharing can be significant. These options may reduce what you pay.

Amgen PROLIA ASSIST Program

Amgen, the manufacturer, offers the PROLIA ASSIST copay card for commercially insured patients. As of 2024, the card can reduce copays to as low as $0 per injection, with a maximum annual savings of $1,050. Medicare and Medicaid beneficiaries do not qualify for the copay card but may qualify for the Amgen Safety Net Foundation, which provides free drug to patients below 400% of the federal poverty level.

Enrollment is available at amgensupportive.com or by calling 1-800-772-6436.

Specialty Pharmacy Negotiation

BCBSM may require Prolia to be dispensed through a contracted specialty pharmacy rather than a retail chain. Contracted specialty pharmacies often have lower negotiated rates than WAC. Ask your BCBSM representative which specialty pharmacies are in-network for your plan, because using an out-of-network specialty pharmacy can result in significantly higher cost-sharing.

Good Faith Estimate and Cost Transparency

Under the No Surprises Act (effective January 2022), providers must supply a Good Faith Estimate of out-of-pocket costs for scheduled services. Ask your prescribing clinic for this estimate before your first Prolia injection. [9]

Clinical Context: When Is Prolia the Right Choice?

Coverage approval is more likely when the clinical rationale is airtight. Understanding the guideline-based indications helps both patients and prescribers frame the case correctly.

AACE/ACE High-Risk Criteria

The AACE/ACE 2020 guidelines define "high fracture risk" as a T-score <-2.5, a prior fragility fracture, or a FRAX 10-year probability of major osteoporotic fracture above 20% (or hip fracture above 3%). [5] Patients meeting any of these criteria are candidates for pharmacotherapy, and denosumab is listed as an appropriate agent.

The guidelines also note that denosumab produces greater gains in bone mineral density at the femoral neck than alendronate, based on head-to-head data from the DECIDE trial (N=1,189), which showed a 1.9% greater BMD increase at the total hip with denosumab compared with alendronate at 12 months (P<0.0001). [10]

Rebound Risk After Discontinuation

One clinically significant fact that affects both prescribing and coverage decisions: stopping denosumab without transitioning to an antiresorptive agent causes rapid bone loss and a rebound increase in fracture risk, including multiple vertebral fractures. The FDA added a warning about this rebound phenomenon to the Prolia label in 2022. [1] This means that once a patient starts Prolia, the payer and prescriber share an obligation to plan for long-term continuation or a structured transition, typically to a bisphosphonate for 12-24 months after the last Prolia dose. This clinical reality can be cited in PA appeals to argue that denying a renewal is clinically harmful, not merely inconvenient.

Renal Impairment and Bisphosphonate Contraindication

Oral bisphosphonates are contraindicated when eGFR falls below approximately 30-35 mL/min. [4] For patients with chronic kidney disease Stage 3b or Stage 4, denosumab may be the only approved systemic antiresorptive option outside of clinical trial settings, because denosumab is not renally cleared. This makes the renal contraindication pathway one of the strongest arguments for PA approval and one of the most common successful appeal strategies.

The BCBSM Prior Authorization Decision Framework for Prolia

The table below summarizes the typical approval pathway based on clinical scenario. Use it as a pre-submission checklist before your prescriber submits the PA.

| Clinical Scenario | Likely PA Outcome | Key Documentation Needed | |---|---|---| | T-score <-2.5, failed alendronate 70 mg weekly x 6 months | High probability of approval | DXA report, pharmacy records of alendronate | | Prior fragility hip fracture, bisphosphonate naive | Likely approval with strong letter of medical necessity | Radiology report, physician letter citing AACE 2020 | | eGFR <35 mL/min, bisphosphonate contraindicated | High probability of approval | Serum creatinine or eGFR lab, prescriber letter | | T-score -2.0 to -2.5 (osteopenia), no fracture | Lower probability; may require FRAX >20% | FRAX printout, additional risk factor documentation | | Premenopausal woman, glucocorticoid-induced bone loss | Requires off-label justification; uncertain | ACR guidelines on glucocorticoid-induced osteoporosis, physician letter | | Renewal after 12 months on Prolia | Generally approved if benefit documented | Updated DXA or bone turnover markers, office note |

How to Check Your Specific BCBSM Plan Coverage

No single answer covers every BCBSM product, because BCBSM administers dozens of distinct plan designs in Michigan. Here is the fastest way to confirm your coverage:

1. Call the member services number on the back of your BCBSM ID card and ask specifically: "Is denosumab (J0897) covered under my plan, what tier is it on, and is prior authorization required?"
2. Ask your prescriber's office to run an electronic benefit investigation through their specialty pharmacy or through BCBSM's provider portal at bcbsm.com/providers before submitting the PA.
3. Download your current Evidence of Coverage document from the BCBSM member portal and search for "specialty" and "denosumab."
4. If Prolia will be administered in a physician's office under a medical benefit, confirm the J-code (J0897, denosumab 1 mg, billed as 60 units) is covered under your medical rather than pharmacy benefit.

The J-code distinction matters for Medicare Advantage members in particular. When Prolia is billed under Part B using J0897, it bypasses the Part D formulary entirely and is subject to Part B cost-sharing rules. [3]

Special Populations and Edge Cases

Men With Osteoporosis

Denosumab 60 mg every 6 months carries FDA approval for men with osteoporosis at high fracture risk. [1] The ADAMO trial (N=242) showed significant BMD gains at the lumbar spine (+5.7% vs. +0.9% placebo) and femoral neck (+2.4% vs. -0.1% placebo) at 12 months (P<0.001). [11] BCBSM generally covers this indication under the same PA criteria as postmenopausal women, but the prescriber must document the male osteoporosis diagnosis explicitly.

Androgen Deprivation Therapy-Induced Bone Loss

Men with prostate cancer receiving ADT lose bone mass rapidly, with annual losses at the femoral neck of 2-3% reported in observational data. [12] Denosumab 60 mg every 6 months is FDA-approved for this indication, and BCBSM coverage generally follows the label, though the PA form may need to specify "ADT-induced bone loss" rather than "osteoporosis" as the diagnosis code (ICD-10 M81.0 vs. M85.80).

Aromatase Inhibitor Therapy in Breast Cancer

Women receiving adjuvant aromatase inhibitors for breast cancer experience significant bone loss, with annual BMD decreases of 1-3% at the lumbar spine. [13] The FDA-approved indication for denosumab in this population is covered by BCBSM, but the oncology team and the prescribing endocrinologist or primary care physician should coordinate to ensure the PA reflects the correct indication and ICD-10 code (Z79.811 for long-term use of aromatase inhibitors).